Great Lakes Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Great Lakes Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,873	Closed	-$204K	–	873
2023 Q1	$204K	Sell	1,873 -567	-23%	-$62.7K	﹤0.01%	771
2022 Q4	$278K	Buy	+2,440	New	+$203K	0.02%	573
2022 Q3	–	Sell	-2,915	Closed	-$233K	–	730
2022 Q2	$233K	Sell	2,915 -233	-7%	-$22.1K	﹤0.01%	612
2022 Q1	$331K	Sell	3,148 -744	-19%	-$72.5K	0.01%	580
2021 Q4	$419K	Sell	3,892 -175	-4%	-$19.1K	0.01%	541
2021 Q3	$445K	Sell	4,067 -640	-14%	-$66.4K	0.01%	535
2021 Q2	$441K	Sell	4,707 -47	-1%	-$4.33K	0.01%	535
2021 Q1	$438K	Buy	4,754 +235	+5%	+$19.8K	0.01%	524
2020 Q4	$331K	Sell	4,519 -101	-2%	-$7.51K	0.01%	534
2020 Q3	$359K	Buy	4,620 +667	+17%	+$45.9K	0.01%	478
2020 Q2	$220K	Buy	+3,953	New	+$169K	0.01%	520
2017 Q4	–	Sell	-556,229	Closed	-$7.05M	–	631
2017 Q3	$7.05M	Buy	+556,229	New	+$7.07M	0.17%	110

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Great Lakes Advisors's HZNP Position: Q2 2023 in Review

Great Lakes Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 1,873 shares — an estimated $204K sold.

Great Lakes Advisors first reported a position in HZNP in Q3 2017 and held it in 12 quarters. The position peaked at $7.05M in Q3 2017. 517 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

Great Lakes Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
Great Lakes Advisors sold 1,873 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $204K.
Great Lakes Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2017 and held it in 12 quarters.
Great Lakes Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $7.05M in Q3 2017.
517 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on Great Lakes Advisors's 13F filing for Q2 2023, filed 10 Aug 2023.